<DOC>
	<DOC>NCT01911897</DOC>
	<brief_summary>To evaluate the safety and performance of the MobiusHD system in subjects with resistant hypertension.</brief_summary>
	<brief_title>Controlling and Lowering Blood Pressure With The MOBIUSHD™ (CALM-FIM_EUR)</brief_title>
	<detailed_description>This is an open-label, multicenter, first-in-man clinical trial to be conducted in Europe. Eligible subjects with stage 2 resistant systemic arterial hypertension currently being treate4d with a minimum of three (3) anti-hypertensive drugs, who consent to study participation will be assigned to treatment with the MobiusHD system. Potential study participants will be consented and then screened at two (2) baseline visits beginning at least 30 days prior to MobiusHD placement. Qualified patients will undergo placement of the MobiusHD under angiographic visualization, and will then be followed for 36 months.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>Office cuff SBP ≥ 160 mmHg measured per protocol instructions (Appendix IV) following at least one (1) month of maximally tolerated therapy with at least three (3) antihypertensive medications, of which at least one (1) must be a diuretic unless patient has history of intolerance, ineffectiveness or contraindications. Any combination medications will be counted per the active ingredient (for example, Zestoretic (Lisinopril +HCTZ) equals two (2) antihypertensive medications) Known or clinically suspected baroreflex failure or autonomic neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hypertension</keyword>
</DOC>